-

Dr Martens shares slump 30%, names new CEO

Dr Martens (LSE: DOCS) shares plummeted over 30% after the company issued another profit warning, this time for the year ending March 2025. The iconic bootmaker’s market value now sits at roughly £629 million, a …

Dr Martens (LSE: DOCS) shares plummeted over 30% after the company issued another profit warning, this time for the year ending March 2025. The iconic bootmaker’s market value now sits at roughly £629 million, a stark contrast to its £3.7 billion valuation at its 2021 debut.

Dr Martens anticipates a significant decline in pre-tax profits, potentially falling to a third of current year levels. This bleak outlook stems from a double-digit drop expected in US wholesale revenue, impacting profitability by an estimated £20 million annually. The company also faces inflationary headwinds of £35 million and ongoing storage costs of £15 million.

CEO Kenny Wilson, announcing his departure, acknowledged the challenges and underlined efforts to reignite US demand. However, he cautioned against a swift recovery in the key market during fiscal year 2025. Dr Martens also cited a mismatch between its operating cost base and current revenue levels.

Ije Nwokorie, the current chief brand officer, will succeed Wilson as CEO. This news follows a profit downgrade in 2023 due to US operational issues and a difficult consumer climate. Dr Martens’ share price has declined a staggering 60% in the past year.


Subscribe to Investomania for more Dr Martens news and updates.

Sign up for Investomania

Subscribe to the Investomania newsletter to have our daily recap delivered directly to your inbox.

No spam. Unsubscribe anytime.